Trinity Biotech Is Running Two Stories at Once — A CGM Breakthrough and an AI Cooling Pivot

A quick disclosure before anything else: Trinity Biotech (Nasdaq: TRIB) trades at roughly a $7-11 million market cap right now — well below our usual $50 million micro-cap floor. We're covering it anyway because the underlying story is genuinely interesting, but readers should treat this explicitly as a nano-cap/distressed-value situation, not a standard micro-cap pick, and size any interest accordingly.

With that out of the way — Trinity Biotech is running two separate narratives simultaneously, and both have real substance behind them.

The CGM+ data. The company released new clinical trial results, drawn from more than 5,000 hours of wear data, showing its next-generation CGM+ continuous glucose monitor can distinguish dangerous nocturnal false lows from harmless dips caused by normal sleep pressure. That's a real, specific technical problem in the CGM category — false low alerts are a leading cause of alarm fatigue and device abandonment among users — and solving it with data rather than marketing claims is a legitimate technical achievement.

The Trinovium pivot. Weeks after launching Trinovium — a subsidiary repurposing the company's healthcare-grade, ultra-high-purity fluid manufacturing expertise for the AI data-center liquid cooling market — Trinity secured Silver Membership in the Open Compute Project (OCP), the industry consortium that essentially gatekeepers hyperscale data center hardware standards. That's a fast, credible entry point into a market projected to grow from roughly $4 billion in 2026 to $27 billion by 2033, and OCP membership is the kind of validation that's hard to fake with a press release alone.

Why we're flagging "Pure Promote / Pump Risk" instead of celebrating it. Three material press releases inside a few weeks, spanning two completely different industries, is an aggressive promotional cadence for a company this small — and Trinity's enterprise value (around $140 million, dominated by debt against a market cap under $11 million) signals a balance sheet under real strain. Real technical milestones can still be wrapped in promotional urgency when a company needs a new story to keep the lights on. Both things can be true at once, and that's exactly the setup investors need to price in here.

The bottom line. If either the CGM+ data or the Trinovium/OCP relationship converts into actual contracts or licensing revenue, this becomes a legitimate turnaround story. Until then, it's a name to watch from a safe distance, not a core holding — and one that sits outside our normal coverage range for a reason.

This article is for informational purposes only and does not constitute investment advice.

Todd Colpron is the Managing Partner of Eliakim Capital, a private investment and strategic advisory firm that manages its own capital while working alongside select family offices and private investors to identify and support exceptional opportunities.